NDAORALTABLET
Approved
Jan 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
41
Data completeness
5/8 — Partial
CADUET (amlodipine and atorvastatin) by Pfizer is drugs, a dihydropyridine calcium channel blocker (amlodipine) and an hmg-coa reductase inhibitor (atorvastatin). First approved in 2004.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CADUET is a fixed-dose combination tablet containing amlodipine (a calcium channel blocker) and atorvastatin (an HMG-CoA reductase inhibitor) approved in 2004. It treats patients requiring concurrent management of hypertension and hypercholesterolemia by reducing blood pressure through vasodilation and lowering cholesterol through hepatic LDL receptor upregulation. The combination addresses two major cardiovascular risk factors in a single pill, improving patient compliance.
$0.222MPart D
LOE ApproachingDeclining
Declining market activity with minimal Part D presence signals a mature product facing generic erosion, requiring defensive commercial strategies and smaller team footprints.
Mechanism of Action
drugs, a dihydropyridine calcium channel blocker (amlodipine) and an HMG-CoA reductase inhibitor (atorvastatin). The amlodipine component of amlodipine and atorvastatin tablets inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The atorvastatin…
Worked on CADUET at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.